{"doi":"10.3390/ijms26167846","title":"Solution Structure of the Broad-Spectrum Bacteriocin Garvicin Q","abstract":"Class IId bacteriocins are linear, unmodified antimicrobial peptides produced by Gram-positive bacteria, and often display potent, narrow-spectrum inhibition spectra. Garvicin Q (GarQ) is a class IId bacteriocin produced by the lactic acid bacterium Lactococcus garvieae. It stands out for its unusual broad-spectrum antimicrobial activity against various bacterial species, including Listeria monocytogenes, Pediococcus pentosaceus, Carnobacterium maltaromaticum, Enterococcus faecalis, and Lactococcus spp. Its protein target is the mannose phosphotransferase system (Man-PTS) of susceptible bacterial strains, though little is known about the precise molecular mechanism behind GarQ’s unusual broad spectrum of activity. In this work, 13C- and 15N-labelled GarQ was recombinantly produced using our previously described “sandwiched” protein expression system in Escherichia coli. We also developed a protocol to purify a uniformly labelled sample of the small ubiquitin-like modifier His6-SUMO, which is produced as a byproduct of the expression procedure. We demonstrated its use as a “free” protein standard for 3D NMR experiment calibrations. The GarQ solution structure was solved using triple-resonance nuclear magnetic resonance (NMR) spectroscopy and was compared with the structures of other Man-PTS-targeting bacteriocins. GarQ adopts a helix–hinge–helix fold, which is contrary to its structural predictions according to AlphaFold 3.","journal":"International Journal of Molecular Sciences","year":2025,"id":528713,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9605,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":227820,"name":"Tess Lamer","orcid":"0000-0002-1511-4540","position":1,"is_corresponding":false},{"id":1407022,"name":"Tamara Aleksandrzak‐Piekarczyk","orcid":"0000-0002-4725-760X","position":2,"is_corresponding":false},{"id":3302,"name":"Ryan T. McKay","orcid":"0000-0002-0255-159X","position":3,"is_corresponding":false},{"id":1407023,"name":"Karizza F. Catenza","orcid":"0009-0008-3571-0535","position":4,"is_corresponding":false},{"id":1407024,"name":"Clarissa S. Sit","orcid":"0000-0002-3984-5567","position":5,"is_corresponding":false},{"id":930631,"name":"Jan K. Rainey","orcid":"0000-0003-0793-5573","position":6,"is_corresponding":false},{"id":1407476,"name":"Kaitlyn M. Towle-Straub","orcid":null,"position":7,"is_corresponding":false},{"id":227826,"name":"John C. Vederas","orcid":"0000-0002-2996-0326","position":8,"is_corresponding":false},{"id":227822,"name":"Marco J. van Belkum","orcid":"0000-0002-9296-6069","position":9,"is_corresponding":false},{"id":1407475,"name":"Tyler Mallett","orcid":null,"position":0,"is_corresponding":true}],"reference_count":65,"raw_metadata":null,"created_at":"2026-07-19T02:50:52.565868Z","pmid":"40869166","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}